Peer-reviewed article

Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial: commentary, author response.

Loo C iD, Alonzo A, Barton D, Berk M, Chatterton ML iD, Dong V, Gálvez V, Mills NT iD, Mitchell PB iD, Sarma S, Somogyi AA, Rodgers A

The British journal of psychiatry : the journal of mental scienceMay 27, 2025Australia, Spain0 citationsDOI: 10.1192/bjp.2024.176

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

NeuroscienceAffective DisordersMajor Depressive DisorderClinical Drug StudiesKetamine/esketamine

View paper

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

Related research

ArticleKetamine

Pharmacologic Approaches to Suicide Prevention.

Zisook S, Domingues I, Compton J

Europe PMC2023

ArticleKetamine

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.

Drozdz SJ, Goel A, McGarr MW +6

Europe PMC2022

ArticleKetamine

Effects of ketamine on individual symptoms and symptom networks of depression in a randomised controlled trial of ketamine for treatment-resistant depression.

Hossein S, Rengasamy M, Uzamere A +5

Europe PMC2025